Table 3.
Pathway of RNA-seq involved in immunity and inflammation responses after infection for four weeks
| Pathway | DEGs with pathway annotation | All genes with pathway annotation | ||||||
|---|---|---|---|---|---|---|---|---|
| 1st w (700) | 2nd w (946) | 3rd w (665) | 4th w (432) | 1st w | 2nd w | 3rd w | 4th w | |
| Jak-STAT signaling | 15 (2.14%) | 22 (2.33%) | 13 (1.95%) | 5 (1.16%) | 577 (1.51%) | 577 (1.51%) | 577 (1.51%) | 577 (1.51%) |
| MAPK signaling | 26 (3.71%) | 29 (3.07%) | 16 (2.41%) | 9 (2.08%) | 1058 (2.76%) | 1058 (2.76%) | 1058 (2.76%) | 1058 (2.76%) |
| apoptosis | 9 (1.29%) | 12 (1.27%) | 5 (0.75%) | 3 (0.69%) | 373 (0.97%) | 373 (0.97%) | 373 (0.97%) | 373 (0.97%) |
| NF-kappa B | 23 (3.29%) | 37 (3.91%) | 11 (1.65%) | 8 (1.85%) | 477 (1.25%) | 477 (1.25%) | 477 (1.25%) | 477 (1.25%) |
| Toll-like receptor signaling | 22 (3.14%) | 22 (2.33%) | 15 (2.26%) | 4 (0.93%) | 405 (1.06%) | 405 (1.06%) | 405 (1.06%) | 405 (1.06%) |
| Natural killer cell mediated cytotoxicity | 36 (5.14%) | 43 (4.55%) | 16 (2.41%) | 8 (1.85%) | 532 (1.39%) | 532 (1.39%) | 532 (1.39%) | 532 (1.39%) |
| Fc gamma R-mediated phagocytosis | 33 (4.71%) | 41 (4.33%) | 20 (3.01%) | 16 (3.7%) | 570 (1.49%) | 570 (1.49%) | 570 (1.49%) | 570 (1.49%) |
| Complement and coagulation cascades | 25 (3.57%) | 28 (2.96%) | 20 (3.01%) | 19 (4.4%) | 459 (1.2%) | 459 (1.2%) | 459 (1.2%) | 459 (1.2%) |
| B cell receptor signaling pathway | 22 (3.14%) | 35 (3.7%) | 15 (2.26%) | 11 (2.55%) | 424 (1.11%) | 424 (1.11%) | 424 (1.11%) | 424 (1.11%) |
| T cell receptor signaling pathway | 15 (2.14%) | 23 (2.43%) | 10 (1.5%) | 11 (2.55%) | 462 (1.21%) | 462 (1.21%) | 462 (1.21%) | 462 (1.21%) |
| Cytokine-cytokine receptor interaction | 21 (3%) | 29 (3.07%) | 22 (3.31%) | 5 (1.16%) | 738 (1.93%) | 738 (1.93%) | 738 (1.93%) | 738 (1.93%) |
| RIG-I-like receptor signaling pathway | 8 (1.14%) | 10 (1.06%) | 6 (0.9%) | 2 (0.46%) | 245 (0.64%) | 245 (0.64%) | 245 (0.64%) | 245 (0.64%) |
| NOD-like receptor signaling pathway | 8 (1.14%) | 9 (0.95%) | 6 (0.9%) | 2 (0.46%) | 343 (0.9%) | 343 (0.9%) | 343 (0.9%) | 343 (0.9%) |
| TGF-beta signaling pathway | 2 (0.29%) | 12 (1.27%) | 6 (0.9%) | 1 (0.23%) | 344 (0.9%) | 344 (0.9%) | 344 (0.9%) | 344 (0.9%) |
| Wnt signaling pathway | 5 (0.71%) | 12 (1.27%) | 3 (0.45%) | 3 (0.69%) | 630 (1.64%) | 630 (1.64%) | 630 (1.64%) | 630 (1.64%) |
| Ubiquitin mediated proteolysis | 5 (0.71%) | 11 (1.16%) | 9 (1.35%) | 1 (0.23%) | 668 (1.74%) | 668 (1.74%) | 668 (1.74%) | 668 (1.74%) |
Note: 1st w, first week after infection; 2nd w, second week after infection; 3rd w, third week after infection; 4th w, fourth week after infection.